HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Thiopental inhibits global protein synthesis by repression of eukaryotic elongation factor 2 and protects from hypoxic neuronal cell death.

Abstract
Ischemic and traumatic brain injury is associated with increased risk for death and disability. The inhibition of penumbral tissue damage has been recognized as a target for therapeutic intervention, because cellular injury evolves progressively upon ATP-depletion and loss of ion homeostasis. In patients, thiopental is used to treat refractory intracranial hypertension by reducing intracranial pressure and cerebral metabolic demands; however, therapeutic benefits of thiopental-treatment are controversially discussed. In the present study we identified fundamental neuroprotective molecular mechanisms mediated by thiopental. Here we show that thiopental inhibits global protein synthesis, which preserves the intracellular energy metabolite content in oxygen-deprived human neuronal SK-N-SH cells or primary mouse cortical neurons and thus ameliorates hypoxic cell damage. Sensitivity to hypoxic damage was restored by pharmacologic repression of eukaryotic elongation factor 2 kinase. Translational inhibition was mediated by calcium influx, activation of the AMP-activated protein kinase, and inhibitory phosphorylation of eukaryotic elongation factor 2. Our results explain the reduction of cerebral metabolic demands during thiopental treatment. Cycloheximide also protected neurons from hypoxic cell death, indicating that translational inhibitors may generally reduce secondary brain injury. In conclusion our study demonstrates that therapeutic inhibition of global protein synthesis protects neurons from hypoxic damage by preserving energy balance in oxygen-deprived cells. Molecular evidence for thiopental-mediated neuroprotection favours a positive clinical evaluation of barbiturate treatment. The chemical structure of thiopental could represent a pharmacologically relevant scaffold for the development of new organ-protective compounds to ameliorate tissue damage when oxygen availability is limited.
AuthorsChristian I Schwer, Cornelius Lehane, Timo Guelzow, Simone Zenker, Karl M Strosing, Sashko Spassov, Anika Erxleben, Bernd Heimrich, Hartmut Buerkle, Matjaz Humar
JournalPloS one (PLoS One) Vol. 8 Issue 10 Pg. e77258 ( 2013) ISSN: 1932-6203 [Electronic] United States
PMID24167567 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Hypnotics and Sedatives
  • Peptide Elongation Factor 2
  • Elongation Factor 2 Kinase
  • Thiopental
  • Oxygen
Topics
  • Animals
  • Brain Injuries (drug therapy, metabolism, pathology)
  • Brain Ischemia (drug therapy, metabolism, pathology)
  • Cell Death (drug effects)
  • Cell Hypoxia (drug effects)
  • Cell Line
  • Elongation Factor 2 Kinase (metabolism)
  • Humans
  • Hypnotics and Sedatives (pharmacology)
  • Mice
  • Neurons (metabolism, pathology)
  • Oxygen (metabolism)
  • Peptide Elongation Factor 2 (metabolism)
  • Protein Biosynthesis (drug effects)
  • Thiopental (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: